Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free ABVC Stock Alerts

ABVC BioPharma (ABVC) Financials

ABVC BioPharma logo
$1.01 -0.07 (-6.48%)
Closing price 04:00 PM Eastern
Extended Trading
$1.01 +0.00 (+0.50%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ABVC BioPharma

Annual Income Statements for ABVC BioPharma

This table shows ABVC BioPharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 9/18/2014 9/30/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.00 -11 -4.24 -7.28 -20 -13 -16 -7.79 -4.90 -7.91
Consolidated Net Income / (Loss)		 0.00 -11 -4.24 -3.93 -11 -12 -16 -8.28 -5.26 -8.38
Net Income / (Loss) Continuing Operations		 0.00 -11 -4.24 -3.93 -11 -12 -16 -8.28 -5.26 -8.38
Total Pre-Tax Income 		0.00 -11 -4.24 -4.01 -11 -11 -16 -8.02 -5.37 -8.35
Total Operating Income		 0.00 -11 -4.14 -3.46 -8.51 -12 -15 -6.77 -4.71 -7.15
Total Gross Profit		 0.00 -0.00 0.00 0.68 0.46 0.35 0.68 -0.15 0.51 0.00
Total Revenue		 0.00 0.00 0.00 0.70 0.48 0.49 1.08 0.22 0.56 0.13
Operating Revenue		 0.00 0.00 0.00 0.70 0.48 0.49 1.08 0.22 0.56 0.13
Total Cost of Revenue		 0.00 0.00 0.00 0.02 0.02 0.01 0.29 0.30 0.00 0.00
Operating Cost of Revenue		 0.00 0.00 0.00 0.02 0.02 0.01 0.29 0.30 0.00 0.00
Total Operating Expenses		 0.00 11 4.14 4.14 8.97 12 16 6.62 5.21 7.15
Selling, General & Admin Expense		 - 0.60 0.81 3.07 4.27 5.75 6.07 5.37 2.26 2.89
Research & Development Expense		 - 10 3.17 1.05 0.55 1.00 2.69 1.06 0.18 0.12
Other Special Charges / (Income)		 - 0.40 0.16 0.02 4.15 - 7.04 0.19 2.77 4.14
Total Other Income / (Expense), net		 0.00 -0.01 -0.10 -0.55 -2.31 0.36 -0.40 -1.32 -0.71 -1.34
Interest Expense		 0.00 0.01 0.10 0.48 0.41 0.23 0.29 1.31 0.83 0.42
Interest & Investment Income		 - 0.00 0.00 0.04 0.10 -0.23 0.18 -0.04 -0.25 -0.83
Other Income / (Expense), net		 0.00 0.00 0.00 -0.11 -2.00 0.81 -0.28 0.03 0.36 -0.09
Income Tax Expense		 0.00 0.00 0.00 -0.08 -0.22 0.83 0.80 0.26 -0.11 0.02
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - -0.29 -0.80 0.80 0.11 -0.49 -0.36 -0.47
Basic Earnings per Share		 ($0.01) ($0.06) ($0.02) ($0.21) ($0.50) ($0.51) ($5.19) ($1.80) ($0.42) ($0.39)
Weighted Average Basic Shares Outstanding		 11.14K 193.98M 213.32M 17.50M 19.72M 25.05M 3.17M 4.34M 11.67M 20.11M
Diluted Earnings per Share		 ($0.01) ($0.06) ($0.02) ($0.21) ($0.50) - - ($1.80) ($0.42) ($0.39)
Weighted Average Diluted Shares Outstanding		 11.14K 193.98M 213.32M 17.50M 19.72M 25.05M 33.08M 4.34M 11.67M 20.11M

Quarterly Income Statements for ABVC BioPharma

This table shows ABVC BioPharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.32 -0.38 -2.83 -0.94 -0.39 -0.73 -0.84 -2.26 -2.04 -3.56 -1.56
Consolidated Net Income / (Loss)		 -3.37 -0.70 -2.93 -1.05 -0.49 -0.80 -0.94 -2.33 -2.08 -3.81 -1.69
Net Income / (Loss) Continuing Operations		 -3.37 -0.70 -2.93 -1.05 -0.49 -0.80 -0.94 -2.33 -2.08 -3.81 -1.69
Total Pre-Tax Income 		-3.37 -0.52 -2.93 -1.16 -0.49 -0.80 -0.94 -2.31 -2.08 -3.81 -1.69
Total Operating Income		 -2.15 -0.51 -2.84 -0.86 -0.30 -0.70 -0.69 -2.29 -1.96 -2.99 -1.57
Total Gross Profit		 -0.01 -0.14 0.00 0.12 0.39 0.00 0.00 0.00 0.00 -0.80 0.00
Total Revenue		 0.02 0.05 0.01 0.11 0.43 0.01 0.01 0.01 0.03 -0.69 0.01
Operating Revenue		 0.02 0.05 0.01 0.11 0.43 0.01 0.01 0.01 0.03 -0.69 0.01
Total Cost of Revenue		 0.03 0.14 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Cost of Revenue		 0.03 0.14 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 2.14 0.37 2.84 0.98 0.69 0.71 0.69 2.29 1.96 2.20 1.57
Selling, General & Admin Expense		 1.18 1.53 0.74 0.65 0.56 0.31 0.62 0.69 0.80 0.78 0.75
Research & Development Expense		 0.14 0.07 0.07 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.03
Other Special Charges / (Income)		 0.82 -1.22 2.03 0.28 0.10 0.36 0.05 1.57 1.14 1.39 0.79
Total Other Income / (Expense), net		 -1.21 -0.06 -0.10 -0.29 -0.22 -0.10 -0.26 -0.03 -0.15 -0.93 -0.13
Interest Expense		 1.22 -0.08 0.18 0.21 0.22 0.22 0.22 0.13 0.03 - 0.05
Interest & Investment Income		 0.04 -0.22 0.00 -0.05 -0.02 -0.18 -0.03 -0.03 -0.01 -0.76 -0.03
Other Income / (Expense), net		 -0.04 0.09 0.08 -0.03 0.02 0.29 -0.01 0.13 -0.11 -0.10 -0.05
Income Tax Expense		 -0.00 0.18 0.00 -0.11 0.00 - 0.00 0.02 0.00 - 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.05 -0.32 -0.09 -0.11 -0.09 -0.06 -0.10 -0.08 -0.04 -0.25 -0.13
Basic Earnings per Share		 ($0.82) ($0.09) ($0.29) ($0.08) ($0.03) ($0.06) ($0.06) ($0.13) ($0.09) ($0.15) ($0.06)
Weighted Average Basic Shares Outstanding		 4.06M 4.34M 9.74M 11.32M 12.41M 11.67M 14.97M 17.39M 23.26M 20.11M 25.45M
Diluted Earnings per Share		 ($0.82) ($0.09) ($0.29) ($0.08) ($0.03) ($0.06) ($0.06) ($0.13) ($0.09) ($0.15) ($0.06)
Weighted Average Diluted Shares Outstanding		 4.06M 4.34M 9.74M 11.32M 12.41M 11.67M 14.97M 17.39M 23.26M 20.11M 25.45M
Weighted Average Basic & Diluted Shares Outstanding		 7.23M 10.56M 10.85M 12.42M - 0.00 - - - 0.00 26.00M

Annual Cash Flow Statements for ABVC BioPharma

This table details how cash moves in and out of ABVC BioPharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 9/18/2014 9/30/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.00 -0.82 0.07 -0.08 4.84 1.59 -5.17 -0.67 0.15 0.44
Net Cash From Operating Activities		 0.00 -3.47 -1.49 -3.13 -4.56 -7.60 -7.40 -4.19 -1.81 -2.99
Net Cash From Continuing Operating Activities		 -0.00 -3.47 -1.49 -3.13 -4.56 -7.60 -9.03 -4.19 -1.81 -2.99
Net Income / (Loss) Continuing Operations		 -0.00 -11 -4.24 -3.93 -11 -12 -16 -8.28 -5.26 -8.38
Consolidated Net Income / (Loss)		 -0.00 -11 -4.24 -3.93 -11 -12 -16 -8.28 -5.26 -8.38
Depreciation Expense		 - - - 0.06 0.04 0.01 0.02 0.03 0.03 0.03
Amortization Expense		 - - - - - - - 0.35 - 0.48
Non-Cash Adjustments To Reconcile Net Income		 0.00 7.77 2.62 0.12 6.59 4.54 7.36 3.12 3.83 5.48
Changes in Operating Assets and Liabilities, net		 0.00 -0.24 0.13 0.63 -0.60 -0.11 -0.11 0.59 -0.41 -0.60
Net Cash From Investing Activities		 0.00 0.00 0.00 -0.04 -0.23 -0.81 -1.72 -0.36 0.00 -1.21
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 -0.04 -0.23 -0.81 -0.12 -0.36 0.00 -1.21
Purchase of Investments		 - - - -0.04 -0.37 -0.79 - -0.34 0.00 -1.41
Other Investing Activities, net		 - - - - - - - - - 0.20
Net Cash From Financing Activities		 0.00 2.65 1.56 3.09 9.57 10.00 4.01 3.87 1.98 4.64
Net Cash From Continuing Financing Activities		 0.00 2.65 1.56 3.09 9.57 10.00 4.01 3.87 1.98 4.64
Repayment of Debt		 0.00 - 0.00 -0.86 -0.77 -0.51 0.00 -1.19 -0.36 -0.55
Repurchase of Common Equity		 - - - - 0.00 -0.85 - 0.00 -0.01 0.00
Issuance of Debt		 0.00 0.00 1.11 2.86 2.72 0.24 0.35 1.46 0.97 0.50
Issuance of Common Equity		 - 2.35 - 0.00 7.62 11 3.66 3.46 0.43 3.31
Other Financing Activities, net		 - 0.30 0.45 1.08 - - - 0.14 0.95 1.38
Cash Interest Paid		 0.00 0.00 0.09 0.17 0.21 0.33 0.29 0.03 0.02 0.03
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.01

Quarterly Cash Flow Statements for ABVC BioPharma

This table details how cash moves in and out of ABVC BioPharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.38 -0.40 -0.06 0.12 0.02 0.07 -0.11 0.32 -0.23 0.46 -1.19
Net Cash From Operating Activities		 -1.36 -0.43 -0.96 -0.21 0.06 -0.70 -0.54 -0.89 -0.96 -1.42 -0.89
Net Cash From Continuing Operating Activities		 -1.36 -0.43 -0.96 -0.22 0.07 -0.70 -0.54 -0.89 -0.96 -1.42 -0.89
Net Income / (Loss) Continuing Operations		 -3.37 -0.70 -2.93 -1.05 -0.49 -0.80 -0.94 -2.33 -2.08 -3.81 -1.69
Consolidated Net Income / (Loss)		 -3.37 -0.70 -2.93 -1.05 -0.49 -0.80 -0.94 -2.33 -2.08 -3.81 -1.69
Depreciation Expense		 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 - - 0.10 - - - - 0.07 0.09 0.21 0.09
Non-Cash Adjustments To Reconcile Net Income		 1.62 0.41 2.21 0.55 0.38 0.69 0.31 1.75 1.19 2.24 0.83
Changes in Operating Assets and Liabilities, net		 0.38 -0.50 -0.34 0.37 -0.14 -0.30 0.09 -0.39 -0.16 -0.06 -0.13
Net Cash From Investing Activities		 -0.07 0.15 0.00 -0.50 0.04 0.46 0.00 -0.67 -0.51 0.73 0.05
Net Cash From Continuing Investing Activities		 -0.07 0.15 0.00 -0.50 0.04 0.46 0.00 -0.67 -0.51 0.73 0.05
Purchase of Investments		 -0.05 0.15 - - 0.04 0.46 0.00 - -0.51 0.67 -0.68
Other Investing Activities, net		 - - - - - - 0.00 - - 0.20 0.73
Net Cash From Financing Activities		 1.66 0.04 0.92 0.80 -0.08 0.34 0.43 1.93 1.20 1.15 -0.34
Net Cash From Continuing Financing Activities		 1.66 0.04 0.92 0.80 -0.08 0.34 0.43 1.93 1.20 1.15 -0.34
Repayment of Debt		 - -0.19 0.00 - 0.04 -0.39 -0.03 -0.07 -0.11 -0.26 -0.76
Issuance of Common Equity		 3.48 -0.02 0.39 0.13 0.03 -0.13 0.00 2.04 0.74 0.53 0.32
Other Financing Activities, net		 - 0.14 0.00 - 0.74 0.21 0.41 - 0.58 0.39 0.10
Cash Interest Paid		 0.01 0.01 0.01 0.01 0.04 -0.04 0.01 0.01 0.01 0.01 0.00
Cash Income Taxes Paid		 - 0.03 0.00 0.03 -0.00 - 0.00 0.00 0.00 0.01 0.01

Annual Balance Sheets for ABVC BioPharma

This table presents ABVC BioPharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2014 9/30/2015 9/30/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.07 1.00 0.18 2.64 6.93 12 14 9.58 7.78 7.54 21
Total Current Assets		 0.00 1.00 0.17 2.64 0.88 6.17 7.65 2.99 1.66 2.18 2.50
Cash & Equivalents		 0.00 0.99 0.17 0.09 0.14 4.27 5.83 0.09 0.06 0.25 0.68
Restricted Cash		 - - - 0.00 0.02 0.73 0.74 1.31 0.66 0.62 0.65
Short-Term Investments		 - - - - - 0.00 0.11 0.08 0.08 0.06 0.06
Accounts Receivable		 - - - 2.55 0.31 0.30 0.43 1.37 1.51 1.16 0.76
Prepaid Expenses		 - 0.00 - 0.00 0.08 0.17 0.53 0.15 0.10 0.10 0.35
Other Current Assets		 - - - 0.00 0.33 0.70 0.00 - - - 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.52 0.51 0.53 0.57 0.57 0.51 13
Total Noncurrent Assets		 0.06 0.00 0.00 0.00 5.53 4.92 5.52 6.02 4.84 4.85 5.73
Long-Term Investments		 - - - - 3.36 1.19 2.09 3.68 3.80 2.26 1.88
Other Noncurrent Operating Assets		 - 0.00 0.00 - 0.70 1.94 1.63 2.22 1.04 2.59 3.85
Total Liabilities & Shareholders' Equity		 0.07 1.00 0.18 2.64 6.93 12 14 9.58 7.78 7.54 21
Total Liabilities		 0.03 0.37 6.56 4.40 7.05 8.94 4.83 6.34 6.53 6.82 7.76
Total Current Liabilities		 0.02 0.02 6.56 4.40 6.81 4.84 3.69 5.54 6.10 6.56 6.16
Short-Term Debt		 - - - 0.00 4.04 2.09 1.64 1.89 0.90 1.79 1.00
Accounts Payable		 0.02 0.00 0.02 - 0.02 0.31 0.39 - 3.55 3.51 4.16
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - 0.00 0.11 0.00 0.01
Other Current Liabilities		 - 0.02 6.50 4.23 0.73 0.32 0.35 0.74 0.83 1.26 0.99
Total Noncurrent Liabilities		 0.02 0.35 0.00 0.00 0.24 4.10 1.14 0.80 0.43 0.26 1.60
Other Noncurrent Operating Liabilities		 - 0.35 - 0.00 0.24 1.48 0.01 0.01 0.43 0.02 1.60
Commitments & Contingencies		 - 0.00 0.00 0.00 - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.03 0.63 -6.38 -1.76 -0.12 2.66 8.87 3.24 1.25 0.72 13
Total Preferred & Common Equity		 0.03 0.63 -6.38 -1.76 -0.15 3.44 8.84 3.10 1.55 1.23 11
Preferred Stock		 0.00 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.03 0.63 -6.38 -1.76 -0.15 3.44 8.84 3.10 1.55 1.23 11
Common Stock		 0.05 1.30 4.94 14 28 41 58 68 74 79 96
Retained Earnings		 -0.02 -0.32 -11 -16 -16 -26 -38 -55 -64 -69 -77
Treasury Stock		 - - - - -9.10 -9.10 -9.10 -9.10 -8.90 -8.91 -8.91
Accumulated Other Comprehensive Income / (Loss)		 - - - - 0.66 0.56 0.54 0.52 0.52 0.45 0.49
Other Equity Adjustments		 - -0.35 - - -4.06 -3.16 -2.26 -1.35 - 0.03 0.36
Noncontrolling Interest		 - - - - 0.03 -0.78 0.03 0.14 -0.30 -0.50 2.19

Quarterly Balance Sheets for ABVC BioPharma

This table presents ABVC BioPharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 17 14 15 7.78 15 16 21 20
Total Current Assets		 2.49 1.79 2.19 2.17 1.47 2.77 3.31 0.65
Cash & Equivalents		 0.50 0.03 0.12 0.00 0.15 0.39 0.19 0.14
Restricted Cash		 0.62 0.63 0.62 0.00 0.61 0.69 0.66 0.00
Short-Term Investments		 0.07 0.08 0.08 0.00 0.07 0.07 0.07 0.06
Accounts Receivable		 1.16 0.90 1.26 0.00 0.54 1.42 1.93 0.33
Prepaid Expenses		 0.14 0.16 0.10 0.11 0.10 0.19 0.45 0.25
Other Current Assets		 - - - - - - - 0.00
Plant, Property, & Equipment, net		 7.95 7.95 7.93 0.53 8.17 8.22 13 13
Total Noncurrent Assets		 6.14 4.72 4.52 0.69 5.24 5.26 5.05 6.26
Long-Term Investments		 4.11 3.75 3.65 0.00 3.88 3.96 2.75 1.85
Other Noncurrent Operating Assets		 2.00 0.97 0.86 0.69 1.35 1.29 2.30 4.41
Total Liabilities & Shareholders' Equity		 17 14 15 7.78 15 16 21 20
Total Liabilities		 7.53 6.97 6.81 6.44 6.92 6.75 6.72 6.90
Total Current Liabilities		 5.36 6.63 6.55 6.25 6.73 6.53 6.54 5.39
Short-Term Debt		 0.85 1.70 1.80 0.90 1.64 1.13 1.03 0.89
Accounts Payable		 - 4.05 3.96 3.59 3.83 4.29 3.99 4.15
Current Deferred & Payable Income Tax Liabilities		 - 0.11 0.00 0.00 - 0.02 0.01 0.01
Other Current Liabilities		 0.95 0.77 0.78 0.39 1.27 1.09 1.52 0.35
Total Noncurrent Liabilities		 2.16 0.32 0.23 0.00 0.17 0.18 0.16 1.51
Other Noncurrent Operating Liabilities		 - - - - - - - 1.51
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 9.06 7.49 7.83 1.34 7.96 9.49 14 13
Total Preferred & Common Equity		 9.10 7.79 8.29 1.64 5.40 7.01 12 11
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 9.10 7.79 8.26 78 5.40 7.01 12 11
Common Stock		 81 86 87 78 84 86 94 97
Retained Earnings		 -62 -69 -70 0.00 -70 -72 -74 -78
Treasury Stock		 -9.10 -8.90 -8.90 0.00 -8.91 -8.91 -8.91 -8.91
Accumulated Other Comprehensive Income / (Loss)		 0.52 0.23 0.44 0.00 0.44 0.48 0.49 0.50
Other Equity Adjustments		 -0.68 -0.23 0.00 0.00 0.03 1.09 0.64 0.42
Noncontrolling Interest		 -0.04 -0.31 -0.47 -0.31 2.55 2.48 2.44 2.06

Annual Metrics And Ratios for ABVC BioPharma

This table displays calculated financial ratios and metrics derived from ABVC BioPharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 54,593,032.00 418,705,794.00 213,746,647.00 213,926,475.00 19,478,168.00 20,813,903.00 28,609,388.00 32,632,329.00 7,231,940.00 7,231,940.00 7,231,940.00
DEI Adjusted Shares Outstanding		 5,459,303.00 41,870,579.00 21,374,665.00 21,392,647.00 1,947,817.00 2,081,390.00 2,860,939.00 3,263,233.00 7,231,940.00 7,231,940.00 7,231,940.00
DEI Earnings Per Adjusted Shares Outstanding		 - -0.26 -0.20 - -3.74 -9.41 -4.49 -5.03 -1.08 -0.68 -1.09
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -31.16% 1.52% 119.62% -79.73% 155.61% -75.95%
EBITDA Growth		 0.00% 0.00% 62.37% 4.73% 10.83% -197.71% -3.98% -41.25% 58.63% 32.26% -56.39%
EBIT Growth		 0.00% 0.00% 62.37% 4.73% 9.43% -194.16% -3.73% -41.31% 56.22% 35.61% -66.86%
NOPAT Growth		 0.00% 0.00% 62.37% 66.32% -73.65% -145.92% -37.62% -29.12% 55.23% 30.47% -51.98%
Net Income Growth		 0.00% 0.00% 61.46% 6.67% 0.00% -169.33% -13.61% -35.53% 49.24% 36.49% -59.29%
EPS Growth		 0.00% 0.00% 66.67% 0.00% 0.00% -138.10% 0.00% 0.00% 0.00% 76.67% 7.14%
Operating Cash Flow Growth		 187.67% 0.00% 57.25% 57.57% 0.00% -45.60% -66.47% 2.62% 43.41% 56.79% -65.07%
Free Cash Flow Firm Growth		 101.26% -2,518.66% -563.45% 140.29% -370.00% 29.87% -46.64% 14.28% 73.36% -102.04% -260.89%
Invested Capital Growth		 -100.00% 0.00% 71.76% -267.87% 105.73% 202.82% 143.68% -73.10% -320.41% 74.41% 2,626.86%
Revenue Q/Q Growth		 0.00% 0.00% 100.00% 0.00% 0.00% -7.25% -5.52% 128.51% -73.10% -5.42% 98.38%
EBITDA Q/Q Growth		 100.00% 0.00% 68.68% -895.35% 0.00% -60.02% -8.39% 13.69% 34.21% 0.40% -26.56%
EBIT Q/Q Growth		 100.00% 0.00% 58.95% -830.07% 0.00% -59.58% -8.34% 13.65% 30.47% 0.33% -35.28%
NOPAT Q/Q Growth		 100.00% 0.00% 6.04% -218.90% 0.00% -77.98% -15.79% 17.98% 27.92% -4.27% -26.42%
Net Income Q/Q Growth		 0.00% 0.00% 4.84% -391.24% 0.00% -57.17% -19.12% 12.83% 31.46% -1.86% -36.06%
EPS Q/Q Growth		 0.00% 0.00% 33.33% 166.30% 0.00% 0.00% 0.00% 0.00% 40.59% -13.51% -56.00%
Operating Cash Flow Q/Q Growth		 -3.95% 0.00% 6.48% 96.70% 0.00% -17.88% -4.64% 21.81% 0.73% -17.67% 3.69%
Free Cash Flow Firm Q/Q Growth		 100.83% -117.48% 10.96% 2,279.67% -363.89% -111.46% 8.65% 30.09% 78.21% -172.85% 11.59%
Invested Capital Q/Q Growth		 -100.00% -0.69% -75.19% -515.31% 129.08% 8,150.62% -23.59% -74.12% -125.15% 83.49% -8.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 97.13% 96.13% 71.52% 63.46% -68.52% 91.18% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -501.06% -2,167.02% -2,219.61% -1,427.59% -2,913.15% -772.01% -5,020.73%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -492.90% -1,760.87% -2,387.16% -1,403.47% -3,099.31% -843.13% -5,328.97%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -508.91% -2,174.71% -2,222.05% -1,429.80% -3,087.37% -777.75% -5,396.92%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -560.52% -2,193.08% -2,454.43% -1,514.71% -3,792.81% -942.37% -6,242.33%
Tax Burden Percent		 0.00% 100.01% 100.02% 200.09% 98.08% 97.96% 107.36% 105.14% 103.19% 97.94% 100.29%
Interest Burden Percent		 0.00% 100.09% 102.50% 207.93% 112.30% 102.94% 102.89% 100.76% 119.05% 123.71% 115.33%
Effective Tax Rate		 0.00% 0.00% 0.00% -0.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -758.53% -404.05% -579.82% 0.00% 0.00% -94.57%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 200.69% -301.28% -444.26% 0.00% 0.00% 101.74%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% -76.52% 195.32% 310.34% 0.00% 0.00% -24.92%
Return on Equity (ROE)		 0.00% 383.16% 104.30% 115.57% 6,302.41% -835.04% -208.73% -269.48% -368.89% -531.91% -119.49%
Cash Return on Invested Capital (CROIC)		 200.00% 0.00% 0.00% 0.00% -2,467.75% -859.23% -487.66% -464.61% 0.00% 0.00% -149.37%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -103.09% -113.35% -86.12% -132.30% -77.64% -56.65% -50.64%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -113.55% -114.31% -95.13% -140.16% -95.38% -68.64% -58.58%
Return on Common Equity (ROCE)		 0.00% 383.16% 104.30% 241.49% 7,622.66% -1,081.92% -222.30% -265.83% -382.29% -747.85% -105.14%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 172.56% 241.49% 72.49% 2,605.42% -308.10% -136.10% -526.45% -532.84% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.00 -7.70 -2.90 -1.39 -2.42 -5.95 -8.19 -11 -4.74 -3.29 -5.01
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -345.03% -1,232.61% -1,671.01% -982.43% -2,169.52% -590.19% -3,730.28%
Net Nonoperating Expense Percent (NNEP)		 0.00% -3,814.39% -1,008.54% -531.81% -317.79% -959.22% -102.77% -135.56% -130.75% -95.44% -196.31%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -220.03% -119.72% -35.02%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 2.87% 3.87% 1.04% 26.60% 138.34% 0.14% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 437.42% 884.69% 1,171.79% 563.41% 2,458.79% 405.21% 2,151.60%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 149.43% 113.79% 204.70% 250.10% 486.84% 32.12% 90.23%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 590.03% 1,856.99% 2,458.68% 1,477.15% 3,030.79% 934.31% 5,328.97%
Earnings before Interest and Taxes (EBIT)		 0.00 -11 -4.14 -3.94 -3.57 -11 -11 -15 -6.74 -4.34 -7.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.00 -11 -4.14 -3.94 -3.52 -10 -11 -15 -6.36 -4.31 -6.74
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 14.05 9.60 66.73 3.24 5.62 3.85
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 14.05 9.60 66.73 3.24 5.62 3.85
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 108.97 100.00 173.20 191.98 23.04 12.34 319.18
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% -2.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 197.60 39.02 27.46 264.28 0.00 0.00 3.88
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 109.74 95.32 161.03 189.83 4.71 9.36 318.51
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 114.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 -0.42 -32.36 1.77 0.31 0.83 0.72 2.80 0.07
Long-Term Debt to Equity		 0.00 0.00 0.00 -0.10 0.00 0.99 0.13 0.24 0.00 0.33 0.00
Financial Leverage		 0.51 0.03 0.03 0.22 7.62 -0.38 -0.65 -0.70 -1.21 -2.08 -0.24
Leverage Ratio		 2.09 -0.21 -0.35 -2.42 -55.50 7.31 2.19 1.92 3.87 7.75 2.04
Compound Leverage Factor		 0.00 -0.21 -0.36 -2.51 -62.33 7.52 2.26 1.94 4.60 9.59 2.35
Debt to Total Capital		 0.00% 0.00% 0.00% -147.27% 103.19% 63.89% 23.76% 45.35% 41.77% 73.68% 6.97%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% -130.03% 103.19% 28.29% 14.10% 31.98% 41.77% 65.08% 6.97%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% -17.25% 0.00% 35.60% 9.67% 13.37% 0.00% 8.61% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% -10.33% 0.67% -10.53% 0.23% 2.32% -13.97% -18.25% 15.29%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 367.93% -3.86% 46.64% 76.01% 52.33% 72.19% 44.57% 77.74%
Debt to EBITDA		 0.00 0.00 0.00 -1.15 -1.15 -0.45 -0.25 -0.17 -0.14 -0.47 -0.15
Net Debt to EBITDA		 0.00 0.00 0.00 0.74 -0.15 0.14 0.55 0.16 0.58 0.27 0.34
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.07 0.00 -0.25 -0.10 -0.05 0.00 -0.06 0.00
Debt to NOPAT		 0.00 0.00 0.00 -3.25 -1.67 -0.79 -0.34 -0.25 -0.19 -0.62 -0.20
Net Debt to NOPAT		 0.00 0.00 0.00 1.05 -0.21 0.25 0.73 0.23 0.78 0.35 0.45
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.38 0.00 -0.44 -0.14 -0.07 0.00 -0.07 0.00
Altman Z-Score		 0.00 -336.57 -13.38 29.29 0.67 -2.66 4.38 6.02 -14.57 -14.72 -3.14
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% -4.48% -20.95% -29.56% -6.50% 1.36% -3.63% -40.60% 12.01%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 0.03 0.60 0.10 0.13 1.27 2.07 0.54 0.27 0.33 0.41
Quick Ratio		 0.00 0.03 0.60 0.05 0.07 0.94 1.72 0.28 0.27 0.22 0.24
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.05 -1.15 -7.60 3.56 -9.62 -6.74 -9.89 -8.48 -2.26 -4.56 -16
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -43,408.10% -6,181.19% -19,748.35% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -112.63 -73.45 22.84 -19.95 -16.65 -43.53 -28.84 -1.72 -5.52 -39.59
Operating Cash Flow to Interest Expense		 0.00 -341.66 -14.36 -4.04 -6.50 -11.27 -33.44 -25.17 -3.19 -2.19 -7.18
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -341.66 -14.36 -8.08 -6.50 -11.27 -33.52 -25.57 -3.20 -2.19 -7.18
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.20 0.05 0.04 0.09 0.03 0.07 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 1.58 1.34 1.20 0.15 0.42 0.14
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.93 0.94 1.96 0.38 1.03 0.02
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.11 0.01 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 230.46 271.40 304.28 2,404.54 870.59 2,608.98
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 3,271.31 25,294.26 0.00 0.00 1,688,130.74 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -3,040.85 -25,022.87 304.28 2,404.54 -1,687,260.15 2,608.98
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -6.55 -1.85 -6.81 0.39 1.18 2.88 0.77 -1.70 -0.44 11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.22 0.62 0.24 0.59 -0.47 -0.52 0.03
Increase / (Decrease) in Invested Capital		 -0.05 -6.55 4.70 -4.96 7.20 0.79 1.70 -2.10 -2.48 1.27 11
Enterprise Value (EV)		 0.00 6.70 6.78 818 77 46 79 204 1.03 5.23 43
Market Capitalization		 0.00 6.88 6.88 410 76 48 85 207 5.03 6.89 43
Book Value per Share		 $0.00 ($0.03) ($0.01) ($0.03) ($0.01) $0.17 $0.31 $0.10 $0.21 $0.11 $0.55
Tangible Book Value per Share		 $0.00 ($0.03) ($0.01) ($0.03) ($0.01) $0.17 $0.31 $0.10 $0.21 $0.11 $0.55
Total Capital		 0.00 -6.38 -1.76 -3.08 3.91 7.37 12 5.92 2.15 2.75 14
Total Debt		 0.00 0.00 0.00 2.26 4.04 4.71 2.76 2.69 0.90 2.03 1.00
Total Long-Term Debt		 0.00 0.00 0.00 0.27 0.00 2.62 1.12 0.79 0.00 0.24 0.00
Net Debt		 0.00 -0.17 -0.09 -1.47 0.51 -1.48 -5.99 -2.46 -3.70 -1.16 -2.27
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.12 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -6.56 -1.85 -8.66 -2.06 -1.59 -1.07 -2.13 -4.34 -3.52 -4.06
Debt-free Net Working Capital (DFNWC)		 0.00 -6.38 -1.76 -8.42 -1.90 3.41 5.60 -0.66 -3.55 -2.59 -2.67
Net Working Capital (NWC)		 0.00 -6.38 -1.76 -10 -5.94 1.33 3.96 -2.56 -4.45 -4.38 -3.66
Net Nonoperating Expense (NNE)		 0.00 3.31 1.35 2.71 1.51 4.64 3.84 5.73 3.54 1.97 3.37
Net Nonoperating Obligations (NNO)		 0.00 -0.17 -0.09 -1.47 0.51 -1.48 -5.99 -2.46 -2.96 -1.16 -2.27
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.06 0.04 0.01 0.02 0.38 0.03 0.50
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -293.11% -328.54% -218.59% -197.80% -1,988.74% -630.01% -3,024.28%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -270.24% 706.84% 1,142.29% -61.53% -1,624.11% -463.63% -1,987.48%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -845.92% 275.04% 807.85% -237.38% -2,035.99% -784.43% -2,729.32%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.36) $0.00 ($5.00) ($5.10) ($5.20) ($2.43) ($0.42) ($0.39)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 11.39M 0.00 2.44M 3.03M 3.17M 4.34M 11.67M 20.11M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.36) $0.00 ($5.00) ($5.10) $0.00 $0.00 ($0.42) ($0.39)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 11.39M 0.00 2.44M 3.03M 3.31M 10.56M 11.67M 20.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.36) $0.00 ($5.00) ($5.10) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 11.88M 0.00 1.97M 2.51M 3.31M 10.56M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 0.00 -7.42 -2.79 -0.96 -2.41 -3.05 -8.19 -5.58 -4.61 -1.35 -2.11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -342.80% -631.65% -1,671.01% -517.88% -2,109.91% -242.31% -1,569.28%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -571.49% -2,238.70% -2,286.18% -1,440.63% -3,675.55% -962.17% -6,224.33%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -1,081.33 -40.00 -50.57 -7.41 -25.94 -47.96 -52.38 -5.13 -5.26 -17.41
NOPAT to Interest Expense		 0.00 -756.94 -28.00 -17.88 -5.02 -14.70 -36.06 -35.99 -3.61 -3.99 -12.04
EBIT Less CapEx to Interest Expense		 0.00 -1,081.33 -40.00 -50.57 -7.41 -25.94 -48.03 -52.79 -5.15 -5.26 -17.41
NOPAT Less CapEx to Interest Expense		 0.00 -756.94 -28.00 -17.88 -5.02 -14.70 -36.14 -36.40 -3.62 -3.99 -12.04
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.07% 0.00% 0.00% -0.14% 0.00%

Quarterly Metrics And Ratios for ABVC BioPharma

This table displays calculated financial ratios and metrics derived from ABVC BioPharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 3,951,388.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00
DEI Adjusted Shares Outstanding		 3,951,388.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00 7,231,940.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.84 -0.05 -0.39 -0.13 -0.05 -0.10 -0.12 -0.31 -0.28 -0.49 -0.22
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -62.42% -92.81% -93.88% 1,694.40% 2,577.39% -69.62% 30.36% -89.05% -93.02% -5,010.17% 0.00%
EBITDA Growth		 42.02% 87.60% -39.11% 60.10% 87.54% 4.14% 73.85% -137.36% -627.44% -618.63% -120.73%
EBIT Growth		 41.92% 87.40% -43.99% 59.62% 87.26% 3.40% 74.57% -142.88% -643.57% -652.45% -131.66%
NOPAT Growth		 42.01% 83.66% -48.90% 60.79% 85.97% -37.65% 75.58% -166.83% -549.77% -325.07% -126.91%
Net Income Growth		 10.82% 84.44% -54.31% 54.76% 85.53% -13.74% 67.75% -122.72% -327.44% -378.63% -78.98%
EPS Growth		 0.00% 94.16% 0.00% 0.00% 96.34% 33.33% 79.31% -62.50% -200.00% -150.00% 0.00%
Operating Cash Flow Growth		 -164.53% 6.64% 36.18% 76.50% 104.43% -63.11% 43.52% -322.93% -1,701.71% -102.10% -65.65%
Free Cash Flow Firm Growth		 -190.02% 2,435.90% -500.10% -243.12% 273.82% -183.10% 91.42% 70.47% -274.16% -669.38% -1,435.01%
Invested Capital Growth		 126.78% -320.41% 378.03% 1,164.83% -138.97% 74.41% 0.53% 5.74% 555.10% 2,626.86% 133.71%
Revenue Q/Q Growth		 160.01% 189.38% -79.97% 1,090.87% 287.95% -96.72% -14.08% 0.00% 147.33% -2,410.49% 101.75%
EBITDA Q/Q Growth		 0.83% 80.84% -534.71% 66.92% 69.04% -47.45% -73.14% -254.94% 5.11% -45.66% 46.82%
EBIT Q/Q Growth		 0.81% 80.56% -547.49% 67.67% 68.71% -47.48% -70.46% -208.81% 4.21% -49.24% 47.52%
NOPAT Q/Q Growth		 1.78% 76.25% -454.53% 69.70% 64.85% -133.06% 1.64% -231.16% 14.41% -52.46% 47.49%
Net Income Q/Q Growth		 -45.48% 79.21% -318.05% 64.22% 53.46% -63.41% -18.54% -147.07% 10.69% -82.98% 55.67%
EPS Q/Q Growth		 0.00% 89.02% -222.22% 72.41% 62.50% -100.00% 0.00% -116.67% 30.77% -66.67% 60.00%
Operating Cash Flow Q/Q Growth		 -51.02% 68.32% -122.04% 77.88% 128.49% -1,265.75% 23.12% -65.64% -7.89% -47.09% 36.98%
Free Cash Flow Firm Q/Q Growth		 -216.90% 140.02% -381.10% -8.84% 241.97% -119.13% 70.96% -274.38% -737.35% 15.49% 42.06%
Invested Capital Q/Q Growth		 1,441.89% -125.15% 394.68% 7.08% -149.11% 83.49% 1,257.78% 12.63% 111.35% -8.32% 7.08%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -86.44% -298.14% 10.08% 106.69% 91.47% 14.08% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -13,744.91% -910.21% -28,848.39% -801.39% -63.96% -2,871.76% -5,786.63% -17,376.53% -6,666.81% 0.00% -12,772.94%
Operating Margin		 -13,566.31% -1,113.53% -30,833.84% -784.63% -71.09% -5,044.85% -5,775.04% -19,124.86% -6,618.46% 0.00% -13,103.93%
EBIT Margin		 -13,791.87% -926.71% -29,962.41% -813.53% -65.61% -2,946.37% -5,845.14% -18,050.13% -6,990.29% 0.00% -13,540.91%
Profit (Net Income) Margin		 -21,204.23% -1,523.57% -31,805.18% -955.49% -114.62% -5,703.33% -7,868.25% -19,440.28% -7,019.79% 0.00% -14,082.81%
Tax Burden Percent		 99.97% 133.39% 100.00% 90.43% 100.07% 100.00% 100.00% 101.02% 100.03% 100.00% 100.00%
Interest Burden Percent		 153.79% 123.25% 106.15% 129.89% 174.56% 193.57% 134.61% 106.61% 100.40% 123.13% 104.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,577.91% 0.00% -548.28% -40.72% -14.19% 0.00% -450.09% -1,120.60% -66.81% 0.00% -146.07%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,503.32% 0.00% -488.48% -6.28% -5.38% 0.00% -432.99% -1,097.35% -44.85% 0.00% -116.08%
Return on Net Nonoperating Assets (RNNOA)		 508.01% 0.00% 166.66% 2.18% 3.24% 0.00% 150.52% 396.01% 18.28% 0.00% 21.95%
Return on Equity (ROE)		 -1,069.90% -368.89% -381.62% -38.54% -10.95% -531.91% -299.58% -724.59% -48.54% 0.00% -124.12%
Cash Return on Invested Capital (CROIC)		 -212.14% 0.00% -308.21% -192.21% 0.00% 0.00% -36.10% -56.11% -154.91% -149.37% -146.84%
Operating Return on Assets (OROA)		 -826.92% -23.30% -183.53% -12.27% -3.18% -214.60% -223.50% -541.64% -32.62% 0.00% -105.01%
Return on Assets (ROA)		 -1,271.35% -38.31% -194.81% -14.41% -5.55% -415.39% -300.86% -583.36% -32.76% 0.00% -109.21%
Return on Common Equity (ROCE)		 -1,089.03% -382.29% -391.60% -40.72% -92.01% -747.85% -255.99% -639.15% -276.89% 0.00% -96.60%
Return on Equity Simple (ROE_SIMPLE)		 -132.77% 0.00% -119.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.51 -0.36 -1.99 -0.60 -0.21 -0.49 -0.49 -1.61 -1.38 -2.10 -1.10
NOPAT Margin		 -9,496.42% -779.47% -21,583.69% -549.24% -49.76% -3,531.40% -4,042.53% -13,387.40% -4,632.92% 0.00% -9,172.75%
Net Nonoperating Expense Percent (NNEP)		 -74.60% -12.62% -59.81% -34.43% -8.81% -14.73% -17.10% -23.24% -21.96% -99.93% -29.98%
Return On Investment Capital (ROIC_SIMPLE)		 - -16.64% -20.89% -6.11% -9.48% -17.93% -4.97% -14.88% -8.77% -14.67% -8.03%
Cost of Revenue to Revenue		 186.44% 302.85% 3.01% 0.17% 0.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 7,442.04% 3,321.32% 8,022.66% 596.41% 131.11% 2,230.21% 5,128.09% 5,750.78% 2,689.53% 0.00% 6,266.65%
R&D to Revenue		 889.64% 157.04% 750.31% 36.86% 8.89% 228.98% 240.51% 277.30% 100.71% 0.00% 275.83%
Operating Expenses to Revenue		 13,479.87% 815.39% 30,843.92% 891.31% 162.55% 5,058.93% 5,775.04% 19,124.86% 6,618.46% 0.00% 13,103.93%
Earnings before Interest and Taxes (EBIT)		 -2.19 -0.43 -2.76 -0.89 -0.28 -0.41 -0.70 -2.17 -2.07 -3.10 -1.62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.18 -0.42 -2.66 -0.88 -0.27 -0.40 -0.69 -2.09 -1.98 -2.88 -1.53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.46 3.24 1.64 1.06 0.11 5.62 2.94 5.52 5.86 3.85 2.29
Price to Tangible Book Value (P/TBV)		 0.46 3.24 1.64 1.06 0.11 5.62 2.94 5.52 5.86 3.85 2.29
Price to Revenue (P/Rev)		 5.20 23.04 165.29 48.50 14.37 12.34 28.29 83.51 1,045.15 319.18 183.97
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.28 0.00 1.99 1.09 0.00 0.00 3.07 6.57 5.88 3.88 2.17
Enterprise Value to Revenue (EV/Rev)		 2.34 4.71 129.42 32.43 15.37 9.36 27.66 80.65 1,044.60 318.51 190.64
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 1.45 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.33 0.72 0.27 0.26 0.67 2.80 0.23 0.14 0.08 0.07 0.07
Long-Term Debt to Equity		 0.24 0.00 0.04 0.03 0.00 0.33 0.02 0.02 0.01 0.00 0.00
Financial Leverage		 -0.34 -1.21 -0.34 -0.35 -0.60 -2.08 -0.35 -0.36 -0.41 -0.24 -0.19
Leverage Ratio		 1.83 3.87 2.73 3.21 2.34 7.75 1.90 1.78 1.83 2.04 1.67
Compound Leverage Factor		 2.82 4.77 2.90 4.17 4.09 15.00 2.56 1.90 1.84 2.51 1.73
Debt to Total Capital		 24.96% 41.77% 21.26% 20.61% 40.13% 73.68% 18.48% 12.08% 7.60% 6.97% 6.47%
Short-Term Debt to Total Capital		 7.06% 41.77% 17.91% 18.29% 40.13% 65.08% 16.77% 10.43% 6.55% 6.97% 6.47%
Long-Term Debt to Total Capital		 17.90% 0.00% 3.35% 2.32% 0.00% 8.61% 1.71% 1.64% 1.05% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.32% -13.97% -3.21% -4.72% -13.66% -18.25% 26.15% 22.94% 15.52% 15.29% 14.99%
Common Equity to Total Capital		 75.36% 72.19% 81.95% 83.79% 3,504.16% 44.57% 55.37% 64.98% 76.88% 77.74% 78.54%
Debt to EBITDA		 -0.31 -0.14 -0.27 -0.33 -0.21 -0.47 -0.80 -0.37 -0.22 -0.15 -0.11
Net Debt to EBITDA		 0.24 0.58 0.33 0.39 -0.21 0.27 1.29 1.08 0.46 0.34 0.14
Long-Term Debt to EBITDA		 -0.22 0.00 -0.04 -0.04 0.00 -0.06 -0.07 -0.05 -0.03 0.00 0.00
Debt to NOPAT		 -0.46 -0.19 -0.38 -0.46 -0.28 -0.62 -1.01 -0.47 -0.30 -0.20 -0.16
Net Debt to NOPAT		 0.35 0.78 0.46 0.55 -0.28 0.35 1.62 1.36 0.62 0.45 0.21
Long-Term Debt to NOPAT		 -0.33 0.00 -0.06 -0.05 0.00 -0.07 -0.09 -0.06 -0.04 0.00 0.00
Altman Z-Score		 -5.52 -11.89 -6.64 -6.51 0.12 -13.00 -5.73 -3.46 0.92 -2.49 -3.97
Noncontrolling Interest Sharing Ratio		 -1.79% -3.63% -2.61% -5.65% -740.07% -40.60% 14.55% 11.79% -470.45% 0.00% 22.17%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.46 0.27 0.27 0.33 0.35 0.33 0.22 0.42 0.51 0.41 0.12
Quick Ratio		 0.32 0.27 0.15 0.22 0.00 0.22 0.11 0.29 0.33 0.24 0.10
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.30 2.12 -5.96 -6.49 9.21 -1.76 -0.51 -1.92 -16 -14 -7.85
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -4.35 0.00 -32.81 -31.33 41.78 -8.13 -2.29 -14.80 -518.10 0.00 -159.06
Operating Cash Flow to Interest Expense		 -1.12 0.00 -5.26 -1.02 0.27 -3.24 -2.42 -6.91 -31.16 0.00 -18.11
Operating Cash Flow Less CapEx to Interest Expense		 -1.12 0.00 -5.26 -1.02 0.27 -3.24 -2.42 -6.91 -31.16 0.00 -18.11
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.06 0.03 0.01 0.02 0.05 0.07 0.04 0.03 0.00 0.01 0.01
Accounts Receivable Turnover		 1.34 0.15 0.09 0.19 0.00 0.42 0.78 0.35 0.00 0.14 0.31
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.19 0.38 0.02 0.04 0.14 1.03 0.07 0.06 0.01 0.02 0.01
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 271.78 2,404.54 3,884.14 1,914.60 0.00 870.59 467.60 1,056.70 0.00 2,608.98 1,182.42
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 1,688,130.74 2,958,176.30 5,087,812.69 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 271.78 2,404.54 3,884.14 1,914.60 0.00 -1,687,260.15 -2,957,708.69 -5,086,755.98 0.00 2,608.98 1,182.42
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6.78 -1.70 5.02 5.38 -2.64 -0.44 5.05 5.69 12 11 12
Invested Capital Turnover		 0.17 -0.47 0.03 0.07 0.29 -0.52 0.11 0.08 0.01 0.03 0.02
Increase / (Decrease) in Invested Capital		 3.79 -2.48 3.97 5.88 -9.42 1.27 0.03 0.31 15 11 6.75
Enterprise Value (EV)		 1.90 1.03 9.99 5.86 9.07 5.23 16 37 71 43 26
Market Capitalization		 4.22 5.03 13 8.76 8.48 6.89 16 39 71 43 25
Book Value per Share		 $2.30 $0.21 $0.80 $0.73 $6.31 $0.11 $0.36 $0.40 $0.52 $0.55 $0.42
Tangible Book Value per Share		 $2.30 $0.21 $0.80 $0.73 $6.31 $0.11 $0.36 $0.40 $0.52 $0.55 $0.42
Total Capital		 12 2.15 9.51 9.86 2.23 2.75 9.76 11 16 14 14
Total Debt		 3.01 0.90 2.02 2.03 0.90 2.03 1.80 1.30 1.19 1.00 0.89
Total Long-Term Debt		 2.16 0.00 0.32 0.23 0.00 0.24 0.17 0.18 0.16 0.00 0.00
Net Debt		 -2.28 -3.70 -2.46 -2.44 0.90 -1.16 -2.91 -3.80 -2.47 -2.27 -1.16
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.21 -4.34 -3.87 -3.37 -3.18 -3.52 -4.45 -3.78 -3.12 -4.06 -4.06
Debt-free Net Working Capital (DFNWC)		 -2.02 -3.55 -3.14 -2.56 -3.18 -2.59 -3.62 -2.64 -2.20 -2.67 -3.86
Net Working Capital (NWC)		 -2.87 -4.45 -4.84 -4.36 -4.08 -4.38 -5.26 -3.76 -3.23 -3.66 -4.74
Net Nonoperating Expense (NNE)		 1.86 0.34 0.94 0.45 0.28 0.30 0.46 0.73 0.71 1.72 0.59
Net Nonoperating Obligations (NNO)		 -2.28 -2.96 -2.46 -2.45 -3.98 -1.16 -2.91 -3.80 -2.47 -2.27 -1.02
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.10 0.01 0.01 0.01 0.01 0.08 0.10 0.21 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 -395.09% -1,988.74% -5,016.35% -1,867.41% -538.82% -630.01% -793.22% -815.45% -4,615.34% -3,024.28% -3,024.71%
Debt-free Net Working Capital to Revenue		 -248.53% -1,624.11% -4,063.93% -1,414.41% -538.82% -463.63% -646.19% -569.03% -3,256.67% -1,987.48% -2,873.81%
Net Working Capital to Revenue		 -353.57% -2,035.99% -6,271.35% -2,412.83% -690.71% -784.43% -938.05% -812.13% -4,776.19% -2,729.32% -3,535.34%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.82) ($0.09) ($0.40) ($0.09) ($0.02) ($0.06) ($0.06) ($0.13) ($0.09) ($0.15) ($0.06)
Adjusted Weighted Average Basic Shares Outstanding		 4.06M 4.34M 9.74M 11.32M 12.41M 11.67M 14.97M 17.39M 23.26M 20.11M 25.45M
Adjusted Diluted Earnings per Share		 $0.00 ($0.09) $0.00 $0.00 ($0.02) ($0.06) ($0.06) ($0.13) ($0.09) ($0.15) ($0.06)
Adjusted Weighted Average Diluted Shares Outstanding		 7.23M 4.34M 10.85M 12.42M 12.41M 11.67M 14.97M 17.39M 23.26M 20.11M 25.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.09) $0.00 $0.00 $0.00 ($0.06) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 7.23M 10.56M 10.85M 12.42M 0.00 0.00 0.00 0.00 0.00 0.00 26.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.94 -1.22 -0.56 -0.40 -0.14 -0.24 -0.45 -0.51 -0.58 -1.13 -0.55
Normalized NOPAT Margin		 -5,892.68% -2,643.55% -6,134.02% -368.60% -33.98% -1,711.58% -3,758.02% -4,219.66% -1,953.17% 0.00% -4,579.74%
Pre Tax Income Margin		 -21,210.52% -1,142.17% -31,805.18% -1,056.66% -114.53% -5,703.33% -7,868.25% -19,243.38% -7,018.01% 0.00% -14,082.81%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1.80 0.00 -15.18 -4.31 -1.27 -1.90 -3.15 -16.74 -67.02 0.00 -32.91
NOPAT to Interest Expense		 -1.24 0.00 -10.94 -2.91 -0.96 -2.28 -2.18 -12.41 -44.42 0.00 -22.29
EBIT Less CapEx to Interest Expense		 -1.80 0.00 -15.18 -4.31 -1.27 -1.90 -3.15 -16.74 -67.02 0.00 -32.91
NOPAT Less CapEx to Interest Expense		 -1.24 0.00 -10.94 -2.91 -0.96 -2.28 -2.18 -12.41 -44.42 0.00 -22.29
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.14% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ABVC BioPharma’s latest quarter shows a business still struggling to turn its revenue base into sustainable profits or cash flow. In Q1 2026, the company reported just $12,000 in revenue, a net loss of $1.69 million, and negative operating cash flow of $894,243. While losses remain large, the balance sheet still carries meaningful asset value and the company did end the quarter with more than $140,000 in cash plus $62,185 in short-term investments.

Here are the main takeaways from the last several quarters:

  • Operating cash outflow improved sequentially in Q1 2026 versus Q4 2025, with operating cash flow narrowing to -$894k from -$1.42 million.
  • Q1 2026 cash from investing activities was slightly positive at $47k, helped by other investing activity.
  • The company still maintains a large asset base, including $12.8 million of net property, plant and equipment and $6.26 million of noncurrent assets in Q1 2026.
  • Q1 2026 book equity remained positive at $10.8 million in common equity and $12.8 million including noncontrolling interests.
  • Revenue remains minimal: ABVC posted only $12,000 in Q1 2026, the same level it reported in several 2025 quarters.
  • Losses have been persistent across the period, ranging from roughly $0.8 million to $3.8 million per quarter in the last four years of data.
  • The company has relied heavily on non-cash adjustments and financing activity to support operations.
  • Share count has fluctuated significantly over time, reflecting dilution and changing capital structure.
  • Q1 2026 net loss was $1.69 million, and net loss attributable to common shareholders was $1.56 million.
  • Operating expenses were far above revenue in Q1 2026, with SG&A of $752k, R&D of $33k, and another $787k of special charges.
  • The company burned cash from operations in every recent quarter shown, including -$894k in Q1 2026 and -$1.42 million in Q4 2025.
  • Short-term debt and other current liabilities remain elevated relative to current assets, which were only $649k in Q1 2026 versus $5.39 million in current liabilities.
  • Current liabilities exceeded current assets by a wide margin, pointing to a strained liquidity position.
  • Equity has been volatile and heavily influenced by issuance activity, which suggests ongoing dilution risk for shareholders.

Longer-term trend: ABVC’s quarterly results show a pattern of very limited revenue, recurring operating losses, and dependence on financing rather than internally generated cash. One encouraging sign is that operating cash burn improved somewhat in the latest quarter, but the company is still not close to breakeven. Investors should watch whether management can meaningfully grow revenue while reducing special charges and tightening operating costs.

07/31/26 03:41 PM ETAI Generated. May Contain Errors.

ABVC BioPharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ABVC BioPharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ABVC BioPharma's net income appears to be on an upward trend, with a most recent value of -$8.38 million in 2025, falling from $0.00 in 2014. The previous period was -$5.26 million in 2024. View ABVC BioPharma's forecast to see where analysts expect ABVC BioPharma to go next.

ABVC BioPharma's total operating income in 2025 was -$7.15 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $7.15 million

Over the last 9 years, ABVC BioPharma's total revenue changed from $0.00 in 2014 to $134.20 thousand in 2025, a change of 13,419,600.0%.

ABVC BioPharma's total liabilities were at $7.76 million at the end of 2025, a 13.9% increase from 2024, and a 22,717.3% increase since 2014.

In the past 10 years, ABVC BioPharma's cash and equivalents has ranged from $0.00 in 2014 to $5.83 million in 2021, and is currently $681.48 thousand as of their latest financial filing in 2025.

Over the last 10 years, ABVC BioPharma's book value per share changed from 0.00 in 2015 to 0.55 in 2025, a change of 55.3%.


Related Companies

Financial statements for NASDAQ:ABVC last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel